Evaluating The Side Effects Of Docetaxel (Taxotere) vs Cabazitaxel (Jevtana)

Many men express great hesitation to move to chemotherapy with both docetaxel (taxotere) and cabazitaxel (Jevtana) because of the side effects which can include alopecia (hair loss), nail changes, neuropathy, and dysgeusia (a distortion of the sense of taste). A group of researchers hypothesized that the adverse side effects (AE) of these two chemotherapy drugs, [...]

Is Cabazitaxel Before Docetaxel The Future Way To Go? *

Chemotherapy for prostate cancer is still limited to just two drugs, docetaxel (Taxotere) and cabazitaxel (Jevtana). Both of these chemotherapy drugs are taxanes, but they seem to be very different in their mode of action. A study published online in Clinical Cancer Research, indicates that cabazitaxel might be more effective for some men than docetaxel. [...]

*After the Failure of Docetaxel Is There A Best Sequence For Other Treatments?: Results of an Italian Multicenter Study

As we all know there are now a number of new drugs available to treat castrate resistant metastatic prostate cancer (mCRPC). The availability of these new drugs (abiraterone acetate aka Zytiga, cabazitaxel aka Jevtana, and enzalutamide aka Xtandi) for use in men with mCRPC after the failure of chemotherapy (with docetaxel) has opened a number [...]

Commonly Used FDA Approved Treatments for Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The first line of treatment for advanced prostate cancer is Androgen (male hormone) Deprivation Therapy or ADT. Once the PSA progresses (climbs) while still on ADT and with testosterone levels

What is the Current Role of Taxanes in the Treatment of Metastatic Prostate Cancer?

Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]

Some Great News For Our European Brothers In Their Fight Against Advanced Prostate Cancer

Things are looking up for our European readers. It must be frustrating for people outside of the United States to read this blog and learn about the many advances we now have in the US which are not available to them. The good news is that Sanofi has just launched Jevtana (cabazitaxel) in the UK [...]

One Man’s Experience Fighting The Side Effects of Jevtana (Cabaziltaxel)

A member of the advanced prostate cancer on-line group recently posted about his experience using the newly approved chemotherapy agent, Jevtana (cabazitaxel). His post included not only a report about his PSA response to the drug, but his experiences with side effects and a suggested method of controlling one of the debilitating side effect, diarrhea. [...]

Medicare/ Trailblazer Rejects Reimbursement for Provenge & Jevtana!

A member of the advanced prostate cancer on-line support group who is the wife of an advanced prostate cancer survivor in New Mexico just informed us that Trailblazer (the MAC that controls New Mexico reimbursements for Medicare and Medicaid) has said they will not pay for her husband to get Provenge. They were also told [...]

Can Our Society Find Its Way To An Honest Dialogue About The Price Of A Human Life?

What is the real cost of approved treatments for advanced prostate cancer and how much we should spend? These questions are rippling through the prostate cancer community and the general population. […]

Sanofi-aventis Announces that Jevtana® (cabazitaxel) Injection Is Now Available in the U.S.

Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana [...]